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Abstract
Background: The primary objective of this study was to examine levels of B-type natriuretic peptide (BNP) in
mechanically ventilated patients with acute lung injury and to test whether the level of BNP would be higher in
patients with right ventricular dilatation and would predict mortality.
Methods: This was a prospective, observational cohort study of 42 patients conducted in the intensive care unit of
a tertiary care university hospital. BNP was measured and transthoracic echocardiography was performed within 48
hours of the onset of acute lung injury. The left ventricular systolic and diastolic function, right ventricular systolic
function, and cardiac output were assessed. BNP was compared in patients with and without right ventricular
dilatation, as well as in survivors versus nonsurvivors.
Results: BNP was elevated in mechanically ventilated patients with acute lung injury (median 420 pg/ml; 25-75%
interquartile range 156-728 pg/ml). There was no difference between patients with and without right ventricular
dilatation (420 pg/ml, 119-858 pg/ml vs. 387 pg/ml, 156-725 pg/ml; p = 0.96). There was no difference in BNP
levels between the patients who died and those who survived at 30 days (420 pg/ml, 120-728 pg/ml vs. 385 pg/
ml, 159-1070 pg/ml; p = 0.71).
Conclusions: In patients with acute lung injury the level of BNP is increased, but there is no difference in the BNP
level between patients with and without right ventricular dilatation. Furthermore, BNP level is not predictive of
mortality in this population.
Introduction
B-type natriuretic peptide (BNP) has been shown to be
useful for the diagnosis of congestive heart failure
(CHF) in patients presenting with acute dyspnea [1]. In
patients with CHF, BNP levels correlate with ventricular
filling pressures and predict adverse outcome [2,3].
Similarly, BNP is elevated in patients with right ventri-
cular (RV) dysfunction secondary to pulmonary hyper-
tension and pulmonary embolism [4-6].
In critically ill patients with respiratory failure that
requires intubation and mechanical ventilation, the diag-
nostic accuracy of BNP is less well established, and the
role of BNP in the evaluation of increased left and right
ventricular filling pressures in this setting is unclear. In
patients with shock, BNP level was not shown to distin-
guish reliably between cardiogenic and septic etiologies
or to correlate with hemodynamics but was shown to be
a predictor of mortality [7].
In patients with hypoxic respiratory failure due to pul-
monary edema, several recent studies have examined the
utility of BNP to distinguish patients with cardiogenic
pulmonary edema from patients with acute lung injury
(ALI) [8-11]. These studies demonstrated that BNP
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levels were higher in patients with cardiogenic pulmon-
ary edema compared with those with ALI but that the
diagnostic utility of BNP was limited because of signifi-
cant overlap. Furthermore, there was no correlation
between BNP and filling pressures and, except in one
study, BNP has not been shown to be a predictor of
mortality.
Whereas in cardiogenic pulmonary edema the increase
of BNP is attributed to left ventricular (LV) pressure and
volume overload, the physiologic mechanisms of
increased BNP levels in patients with ALI are poorly
understood. By definition, patients with ALI are charac-
terized by normal or low left-sided filling pressures [12].
However, it is well recognized that a subset of patients
with ALI develops RV hypertension and RV overload
[13-15]. Thus, it is conceivable that increased BNP levels
in patients with ALI is due to increased RV filling pres-
sures or that right ventricular enlargement encroaches
on the left ventricle through septal shift, causing
decreased LV compliance and mild increase in LV filling
pressures. Therefore, we hypothesized that BNP in
mechanically ventilated patients with ALI would be
higher in patients with RV hypertension, dilatation, and
dysfunction.
Methods
Study design and patient selection
This was a prospective, observational, cohort study con-
ducted in the intensive care unit of a tertiary care uni-
versity hospital. The protocol was approved by the
institutional review board, and informed consent was
obtained from patients or their surrogates. All patients
with ALI who were admitted to the adult intensive care
unit of Moffitt-Long Hospital, University of California
San Francisco between December 2004 and May 2006
were eligible for the study. Inclusion criteria were age
18 years or older, positive pressure ventilation via an
endotracheal tube or tracheostomy, and diagnosis of
ALI. The definition of ALI was according to the Ameri-
can-European Consensus Conference criteria: PaO2/
FiO2 ratio < 300, acute onset bilateral infiltrates on a
chest radiograph, and pulmonary artery wedge pressure
< 18 mmHg, or no clinical evidence of left atrial hyper-
tension. Patients were excluded if they had the diagnosis
of ALI for more than 48 hours, known severe chronic
obstructive lung disease (defined as a Forced Expiratory
Volume in 1 second [FEV1] < 50% predicted, history of
intubation secondary to chronic obstructive pulmonary
disease, receiving home oxygen therapy or chronic sys-
temic steroids), preexisting primary or secondary pul-
monary hypertension, or a history of systolic heart
failure (heart failure with left ventricular ejection frac-
tion < 40%). Patients not expected to survive more than
6 months for other reasons than ALI (terminal cancer,
end-stage liver disease with Child-Pugh score more than
12, not committed to full support) also were excluded.
Of 188 eligible patients, 42 patients were enrolled who
had no exclusion criteria and a surrogate was available
to sign informed consent.
Clinical data collection
The primary etiology of ALI was determined based on a
detailed review of clinical history. Sepsis was defined as
suspected infection and presence of at least two of the
systemic inflammatory response syndrome (SIRS) cri-
teria. Pneumonia was defined as new infiltrate on chest
radiograph and presence of at least two of the following
three criteria: fever (temperature > 38.3°C), leukocytosis
(white blood cell count > 12,000/mm3), or purulent
secretions. As a cause of ALI, aspiration had to be wit-
nessed or confirmed by obtaining gastric contents from
the endotracheal tube. Baseline clinical characteristics
and demographic data were recorded on day 1.
APACHE II scores were calculated at the time of the
enrollment into the study. Physiologic and hemody-
namic data were recorded on day 1 and day 3 after
enrollment in the study.
Study procedures
Standard transthoracic echocardiograms were obtained
using the Siemens Acuson Sequoia (Siemens Ultra-
sound, Mountain View, CA) or Phillips Ultrasound 5500
(Andover, MA) ultrasound systems. All echocardiograms
were reviewed by an experienced cardiologist (XR) who
was blinded to clinical and hemodynamic information.
RV size was evaluated according to standard echocar-
diography laboratory protocol based on the recommen-
dations of the American Society of Echocardiography
[7]. Semiquantitative assessment of RV size was per-
formed based on apical four-chamber and subcostal
views. RV was categorized as normal (RV size < LV size
with the cardiac apex formed by the LV and an RV area
≤0.6 of LV), mildly dilated (enlarged RV size but < LV
size), moderately dilated (RV size = LV size), and
severely dilated (RV size > LV size). RV systolic function
was categorized qualitatively as normal, mildly reduced,
moderately reduced, or severely reduced.
End-diastolic and end-systolic volumes and left ventri-
cular ejection fraction were calculated by using the two-
dimensional biplane method of discs. Cardiac output
(CO) was calculated by using the standard volume flow
formula (the product of LV outflow (LVOT) velocity
time integral, LVOT area, and heart rate).
Patterns of LV diastolic dysfunction were based on
mitral inflow E/A ratios of peak velocities at early rapid
filling (E) and late filling due to atrial contraction (A)
and systolic or LV diastolic dominant pulmonary venous
flow using VTI. Based on previously published criteria,
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normal LV diastolic pattern was defined as E/A ratio of
0.75 to 1.5 and systolic dominant pulmonary venous
flow. Impaired relaxation pattern (mild LV diastolic dys-
function) was defined as E/A ratio < 0.75 and systolic
dominant pulmonary venous flow. Pseudonormal pat-
tern (moderate LV diastolic dysfunction) was defined as
E/A ratio of 0.75 to 1.5 and LV diastolic dominant pul-
monary venous flow. Restrictive pattern (advanced LV
diastolic dysfunction) was defined as E/A ratio > 1.5 and
LV diastolic dominant pulmonary venous flow.
RV systolic pressure was calculated by estimating the
systolic pressure gradient across the tricuspid valve
using the modified Bernoulli equation [16,17] and add-
ing this value to the right atrial (RA) pressure. RA pres-
sure was directly measured using central venous
catheter at the time of the echocardiogram. In the
absence of a transpulmonic gradient, PA systolic pres-
sure was used interchangeably with RV systolic pressure
[18].
Plasma for BNP measurements was collected at the
time of enrollment in tubes containing potassium EDTA
and was measured by clinical laboratory personnel
blinded to the clinical status of the patients. The mea-
surement was done with a validated immunoassay
(Triage; Biosite, San Diego, CA).
Dead space fraction was measured using the NICO®
Cardiopulmonary Management System (Novametrix,
Wallingford, CT). This device uses volumetric capnogra-
phy [19] to calculate the partial pressure of mixed
expired CO2, which is then used in the Enghoff modifi-
cation of the Bohr equation [20].
Statistical analysis
Data analysis was conducted using STATA 9.0 (Stata-
Corp, College Station, TX). BNP concentrations were
expressed as median and 25-75% interquartile range
(IQR). To examine the relationship between the BNP
levels and other variables, the BNP levels were log-trans-
formed to achieve normality. We used Student’s t test
for the between group comparisons. The Pearson corre-
lation was used to examine the relation between the
BNP levels and other continuous variables.
Results
Baseline characteristics
Of the 42 patients enrolled in the study, 19 were male
and the mean age was 62 ± 17 years. Demographics,
etiology of ALI and comorbidities are summarized in
Table 1. Baseline physiological variables are summarized
in Table 2. Of note, patients were ventilated with a low
tidal volume, lung protective protocol with a target pla-
teau pressure less than 30 cmH2O. BNP level was ele-
vated in mechanically ventilated patients with ALI
(median 420 pg/ml; 25-75% IQR 156-728 pg/ml).
Table 1 Baseline demographics and clinical
characteristics of the 42 patients with acute lung injury
Clinical characteristic Value
Age 62 ± 17
Sex (male) 19 (45)
Primary etiology of ALI/ARDS
Pneumonia 20
Sepsis 8
Aspiration 13
TRALI 1
Type of admission
Medical 28 (66)
Scheduled surgical 7 (17)
Unscheduled surgical 7 (17)
Underlying medical illness
Chronic liver disease 6 (14)
Glucocorticoids 2 (5)
Coronary artery disease 6 (14)
Congestive heart failure 3 (7)
Chronic renal insufficiency 2 (5)
Metastatic cancer 1 (2)
Hematologic malignancy 2 (5)
AIDS 2 (5)
Diabetes mellitus 12 (28)
AIDS = acquired immunodeficiency syndrome; TRALI = transfusion related
acute lung injury
Data are means ± standard deviations or number of patients with
percentages in parentheses
Table 2 Baseline physiological variables of the 42
patients with acute lung injury
Baseline physiological variables Value
APACHE II 21 ± 7
SAPS II 45 ± 14
Lung injury score 2.67 ± 0.7
Oxygenation index 10.8 ± 7
PaO2/FiO2 177 ± 80
Compliance (ml/cmH2O) 35 ± 9
Plateau pressure (cmH2O) 23 ± 4
Peak inspiratory pressure (cmH2O) 27 ± 5
Mean airway pressure (cmH2O) 15 ± 4
Positive end-expiratory pressure (cmH2O) 9.7 ± 3.6
Tidal volume (ml) 441 ± 99
Tidal volume per kg IBW (ml/kg) 7 ± 1.3
Dead space fraction 0.56 ± 0.1
APACHE II = acute physiology and chronic health evaluation; SAPS II =
simplified acute physiology score; PaO2/FiO2 = ratio of the partial pressure of
arterial oxygen and the fraction of the inspired oxygen; IBW = ideal body
weight
Data are means ± standard deviations
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BNP levels and right ventricular dilatation
Right ventricular (RV) volume and systolic function was
normal in 31 patients (72%), and right ventricular dilata-
tion was present in 11 patients (26%) (Table 3). Three
patients with moderate ventricular dilation also exhibited
right ventricular systolic dysfunction. There was no dif-
ference in BNP between patients with and without RV
dilatation (420 pg/ml vs. 387 pg/ml, p = 0.96; Figure 1).
BNP levels and mortality
Of the 42 patients enrolled, 15 patients died (36%) and 27
patients survived at 30 days (64%). There was no differ-
ence in BNP levels between the patients who died and
those who survived (420 pg/ml vs. 385 pg/ml, p = 0.71;
Figure 2). After stratification by renal failure (defined as a
creatinine > 2 mg/dl) or shock (presence of vasopressors),
BNP levels remained nondiscriminatory.
BNP levels and relationship with other physiologic
variables
There was a modest correlation between BNP levels and
APACHEII (r = 0.38, p = 0.01) and SAPSII (r = 0.35, p
= 0.03). There was a moderate negative correlation
between heart rate and BNP levels (r = -0.35, p = 0.03),
but there was no correlation between BNP levels and
cardiac output, cardiac index, ejection fraction, systolic
pulmonary artery pressure, or central venous pressure.
There also was no relationship between BNP levels and
net fluid balance for the previous 24 h and 8 h. Further-
more, there was no correlation with pulmonary physio-
logic variables, including PaO2/FiO2 ratio, oxygenation
index, pulmonary compliance, and level of PEEP or lung
injury score with BNP. However, there was a moderate
correlation between BNP levels and pulmonary dead
space fraction (r = 0.39, p = 0.01).
Discussion
In this study, the levels of plasma BNP in patients with
early ALI were modestly elevated and the range of dis-
tribution was wide. However, there was no difference in
BNP levels in patients with or without RV dilatation or
dysfunction and no relationship between BNP and
mortality.
Table 3 Hemodynamic and echocardiographic variables
of the 42 patients with acute lung injury
Variable Value
CVP (mmHg) 9.5 ± 4
SPAP (mmHg)* 42.1 ± 9.1
LVEF (%) 65 ± 7
Cardiac output (L/min) 6 ± 1.9
Cardiac index (L/min/m2) 3.2 ± 1
Diastolic dysfunction
Present 18 (43)
Impaired relaxation 15 (37)
Pseudonormalization 1 (2)
Restrictive pattern 2 (4)
Not present 11 (26)
Could not be assessed 13 (31)
Tachycardia 8 (20)
Atrial fibrillation 3 (7)
Other 2 (4)
RV dilation 11 (26)
RV dysfunction 3 (7)
CVP = central venous pressure; SPAP = systolic pulmonary artery pressure;
LVEF = left ventricular ejection fraction; RV = right ventricle
Data are means ± standard deviations or number of patients with
percentages in parentheses
*SPAP available in 39 subjects
Figure 1 Boxplot summary of BNP in patients with and
without right ventricular (RV) dilatation. Median levels of BNP
were 387 (25-75% IQR 156-725) pg/ml in patients without RV
dilation compared with 420 (25-75% IQR 119-858) pg/ml in patients
with RV dilatation, which was not statistically significant (p = 0.96).
Figure 2 Boxplot summary of BNP levels in survivors and
nonsurvivors. Median levels of BNP were 385 (25-75% IQR 159-
1070) pg/ml in patients who survived compared with 420 (25-75%
IQR 120-728) pg/ml in patients who died (p = 0.71).
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Increased levels of plasma BNP in patients with ALI/
ARDS have been previously reported by other authors
in several observational studies [8-11]. However, it is
not clear what pathophysiological mechanisms are pri-
marily responsible for the increased BNP levels in this
patient population. Pulmonary hypertension causing
right heart strain, leading to release of BNP from the
right ventricular myocardium has been the most com-
monly implicated mechanism [21,22]. Several other
mechanisms have been proposed. Hypoxia has been
shown to increase cardiac gene expression of BNP
[23,24] and decrease lung expression of the NPR-C
clearance receptor leading to increased plasma levels of
BNP in animal models [25]. Transcription of the BNP
gene has been described not only in cardiac myocytes
but also in the lung [26]. Thus, it has been suggested
that BNP is released in lung tissue in response to pul-
monary capillary leakage [27].
Pulmonary hypertension with RV dysfunction is a
well-recognized complication of ALI in mechanically
ventilated patients [28-30]. The incidence of cor pulmo-
nale, historically documented to be up to 60% [14], has
decreased with the introduction of low tidal volume
lung-protective ventilation, but it is still reported to be
approximately 25% in an article published in 2001 [31].
There is evidence from other patient populations to
support the hypothesis that elevated BNP levels in
patients with ALI are caused by RV strain. In patients
with isolated RV dysfunction due to variety of condi-
tions, BNP levels have been shown to be elevated. For
example, patients with chronic respiratory failure who
develop cor pulmonale have significantly higher BNP
levels compared with patients with chronic respiratory
failure without cor pulmonale or controls [32,33]. In
patients with idiopathic pulmonary hypertension, BNP
was elevated and was correlated with the severity of RV
dysfunction and outcome [5,6]. Similar relationships
have been demonstrated in patients with pulmonary
embolism complicated by RV dysfunction, where BNP
levels were significantly higher and predictive of mortal-
ity [4,34,35].
However, in contrast to those findings, our study
showed no difference in the plasma levels of BNP in
patients with or without RV dilatation. Furthermore,
there was no correlation between systolic pulmonary
artery pressure and BNP levels. The different findings
may be explained by the timing of measurements
obtained. Pulmonary hypertension with subsequent RV
dilatation and dysfunction in mechanically ventilated
patients with ALI is a result of a combination of factors.
These include abnormalities of pulmonary blood flow
due to formation of microthrombi in the pulmonary
vasculature, hypoxemic vasoconstriction, and positive
end-expiratory pressure. In our study, BNP levels and
echocardiographic measurements were performed early
in the course of the disease (as soon as possible after
the diagnosis of ALI was made), thus potentially mini-
mizing the effect of these factors on BNP levels, pul-
monary artery pressures, and RV geometry and
function. However, although the systolic pulmonary
artery pressures were significantly elevated and BNP
levels were markedly elevated, there was no relationship
between these two variables. Additionally, BNP did not
correlate with RV dilatation. Thus, our study suggests
that BNP elevation in the early stages of ALI may not
be caused by RV strain alone.
BNP has been established to be a predictor of mortality
in a variety of chronic and acute conditions, including
congestive heart failure, coronary artery disease, acute
coronary syndromes [36,37], and acute pulmonary embo-
lism [4]. In critically ill patients, the prognostic value of
elevated BNP is less clear. In several studies, BNP has
been predictive of outcome in patients with cardiogenic
and septic shock [7,38,39]. However, in a mixed popula-
tion of patients who present with severe sepsis and septic
shock, the results are inconsistent; some studies have
shown BNP to be predictive of mortality [40], others
have not [41]. Similarly, in patients presenting with
hypoxic respiratory failure due to CHF or ALI, the stu-
dies have shown conflicting results. Jefic et al. [9] showed
no relationship of BNP with mortality in 41 critically ill
patients with respiratory failure (909 ± 264 in survivors
vs. 841 ± 171 in nonsurvivors). Rana et al. [42] in a study
of 204 patients who presented with pulmonary edema
found that BNP levels did not differ between survivors
and nonsurvivors (median 528 vs. 774, p = 0.24; O. Gajic,
personal communication). Our data are consistent with
those findings. In contrast, in a study by Karmpaliotis et
al. [10], BNP showed a strong graded relationship with
mortality risk in 79 subjects admitted to the ICU with
hypoxic respiratory failure. In the subgroup of patients
with ALI (n = 51), this relationship did not reach statisti-
cal significance but the trend was present (p = 0.07). We
are unable to fully explain the discrepancies between
these studies, but these may be partially attributed to dif-
ferent patient populations, study designs, and statistical
analyses. We found interesting that Karmpaliotis et al.
elected to analyze the mortality data using tertiles of
BNP; however, using this method to analyze our data did
not change our results. Also, in their study, 52% of the
patients with ALI were in shock, and BNP has been
shown to predict mortality in patients with shock.
Because the authors did not stratify for the presence of
shock, it is possible that shock could have accounted for
the significant relationship with mortality.
RV dysfunction has been associated with an increased
risk of death in patients with ALI [43-46]. In our study,
we did not find a relationship between RV dilatation as
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a measure of RV dysfunction and mortality. However,
compared with other studies that have shown this asso-
ciation, our study was modest in size. Furthermore, in
addition to receiving lung protective ventilation, our
patients also received relatively “RV protective” ventila-
tion, as has been suggested by Bouferrache and Vieil-
lard-Baron [46]. Specifically, our patients received
protocolized low tidal volume ventilation with a target
plateau pressure of 30 cmH2O or less and relatively low
PEEP (following the protocol described in [47]) and had
minimal hypercapnia (only one subject had a paCO2 >
50 mmHg). Thus, perhaps the impact of ALI on RV
dysfunction and associated mortality was reduced by
our overall ventilatory approach, despite the fact that
the ventilatory approach was not specifically modified
after the detection of RV dysfunction by echocardiogra-
phy in a protocolized fashion in this study.
The strength of our study includes its prospective
design, rigorous collection of clinical and hemodynamic
variables, and blinded interpretation of echocardiograms.
However, some limitations should be mentioned. First,
because our study was single-center and prospective, the
sample size was modest and may limit our conclusions.
Second, we used only a single measurement of BNP.
Both echocardiography and BNP levels were obtained as
soon as feasible after the diagnosis of ALI and every
effort was made to coordinate these measurements.
Because BNP has half-life of approximately 20 minutes
and is known to fluctuate with changes in loading con-
ditions, serial measurements of BNP may have been
more useful. However, previous studies have shown that
daily BNP levels in ICU patients do not change signifi-
cantly [11,41].
In summary, in patients with acute lung injury the
plasma levels of BNP are increased, yet the reasons for
this increase remain unclear. In this study, BNP levels
were elevated regardless of right ventricular dilatation or
dysfunction and an elevated BNP level was not predic-
tive of mortality in this population of patients with ALI.
Conclusions
The diagnostic utility of BNP is not well established in
critically ill patients with hypoxemic respiratory failure
attributed to ALI. We examined the association of BNP
levels with RV dilatation and with patient outcomes
(mortality) in patients with ALI. Although BNP levels
were elevated in patients with ALI, there was no asso-
ciation with RV dilatation or mortality in our prospec-
tive cohort study. Therefore, BNP seems to have limited
diagnostic utility in this context.
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